Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is currently known as the most common liver problem, characterized by excessive lipid accumulation in hepatocytes, which may progress to other liver diseases such as nonalcoholic steatohepatitis, hepatic tissue fibrosis, liver cirrhosis, and failure or hepatocellular carcinoma. Since NAFLD is positively associated with the development of obesity, insulin resistance, and ultimately type 2 diabetes mellitus, it is often regarded as the hepatic manifestation of the metabolic syndrome. No pharmacologic treatment has yet been proven for this disease. For most patients with presumed or confirmed NAFLD, the only proven strategy is to offer lifestyle advice that can lead to sustained weight loss. Since insulin resistance, oxidative stress, inflammation, and necro-apoptosis are involved in NAFLD pathogenesis, it seems that every potential therapeutic agent should target one or some of these pathologic events. There are many well known anti-oxidants, anti-inflammatory, and insulin sensitizer dietary supplements which have shown beneficial effects on NAFLD improvement in animal and human studies. The purpose of this review is to explore the existing evidences on dietary supplements considered to have hepatoprotective properties, and to present some proposed mechanisms by which they may protect against NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M. L., Perotti, G., et al. (2009) · Hepatology · doi:10.1002/hep.22848 · Cited by 1,434
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O’Connor, H. T., & George, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.018 · Cited by 569
N-3 polyunsaturated fatty acid regulation of hepatic gene transcription
Jump, D. B. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ffaf6a · Cited by 443
Highly Purified Eicosapentaenoic Acid Treatment Improves Nonalcoholic Steatohepatitis
Tanaka, N., Sano, K., Horiuchi, A., Tanaka, E., Kiyosawa, K., & Aoyama, T. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31815591aa · Cited by 248
Teran-Garcia, M., Adamson, A. W., Yu, G., Rufo, C., Suchankova, G., Dreesen, T. D., Tekle, M., Clarke, S. D., & Gettys, T. W. (2007) · Biochemical Journal · doi:10.1042/bj20061722 · Cited by 104
Tauriainen, E., Luostarinen, M., Martonen, E., Finckenberg, P., Kovalainen, M., Huotari, A., Herzig, K.-H., Lecklin, A., & Mervaala, E. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/525094 · Cited by 81
Cited by
Lipidomics for studying metabolism
Han, X. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.98 · Cited by 718
The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)
Safari, Z., & Gérard, P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03011-w · Cited by 502
Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., & Hekmatdoost, A. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.068890 · Cited by 405
Self-citationNon-alcoholic fatty liver and the gut microbiota
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.06.003 · Cited by 241
“Additional treatments include anti-inflammatory drugs, anti-oxidants, lipid-lowering agents, and insulin sensitizers, as well as supplements such as vitamins [125].”
BackgroundGinger in gastrointestinal disorders: A systematic review of clinical trials
Nikkhah Bodagh, M., Maleki, I., & Hekmatdoost, A. (2019) · Food Science & Nutrition · doi:10.1002/fsn3.807 · Cited by 221
Metadata
- Authors
- Eslamparast, T.
- Venue
- World Journal of Hepatology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2014
- Volume
- 7
- Issue
- 2
- Pages
- 204
- ISSN
- 1948-5182 (ISSN-L)
- OpenAlex
- W2043564585
- Cited by
- 77
- References
- 10
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.4254/wjh.v7.i2.204
- The paper
- Eslamparast, T. (2014). Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World Journal of Hepatology. https://doi.org/10.4254/wjh.v7.i2.204
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.